{"disease":{"id":"pancreatic-cancer-adult","name":"pancreatic cancer adult"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06717295","title":"The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Javier Toledo","has_results":false},{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06388967","title":"Pancreatic Cancer Detection Consortium","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05006131","title":"Pancreatic Cancer Screening for At-risk Individuals","phase":"","overall_status":"RECRUITING","enrollment_count":1395,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT06822413","title":"Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06747481","title":"Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":323,"lead_sponsor_name":"University of Las Palmas de Gran Canaria","has_results":false},{"nct_id":"NCT07529626","title":"Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":320,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT04136522","title":"Usefulness of the Artery First Approach in Pancreatic Cancer Surgery","phase":"NA","overall_status":"UNKNOWN","enrollment_count":268,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT07277452","title":"Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":156,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT03042442","title":"Relation Between Cachexia, Diabetes and periNeural Invasion in PANcreatic Cancer- Biomarkers Substudy","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Iuliu Hatieganu University of Medicine and Pharmacy","has_results":false},{"nct_id":"NCT06218914","title":"Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07184047","title":"Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT03854110","title":"Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":64,"lead_sponsor_name":"Geistlich Pharma AG","has_results":false},{"nct_id":"NCT06938503","title":"AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT06584227","title":"Adebrelimab and Chidamide for Pancreatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Liu Xiufeng","has_results":false},{"nct_id":"NCT01537107","title":"Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06800469","title":"Gut Microbiota Analysis in Patients Undergoing Duodencephalopancreasectomy for Pancreatic Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03152487","title":"Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis","phase":"NA","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"AdventHealth","has_results":false},{"nct_id":"NCT01924260","title":"Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Edward Kim","has_results":false},{"nct_id":"NCT01497392","title":"Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT02511821","title":"Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT02293954","title":"Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT06852014","title":"Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): A Mechanistic Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","has_results":false},{"nct_id":"NCT05605197","title":"U87 CART in Treatment of Advanced Solid Tumor","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","has_results":false},{"nct_id":"NCT05238831","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04100694","title":"Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Merus B.V.","has_results":false},{"nct_id":"NCT00033241","title":"Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":null,"lead_sponsor_name":"OSI Pharmaceuticals","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}